Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingredients used in its Alzheimer’s treatment Kisunla, which 澳洲幸运5官方开奖结果体彩网:recently was approved in the U.S.

The pharmaceutical giant is investing $1 billion to expand its manufacturing site in Limerick, following another $1 billion investment announced in March 2023. The facility will produce the active ingredients for the company's Alzheimer's disease portfolio and other medicines.

In July, Eli Lilly received 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration approval for Kisunla after studies showed that the drug was ab🧸le to slow the progression of the disease.

Other Irish Investmen♋t Will Boost Obesity𝓰 Drug Production

Eli Lilly is also spending $800 million to expand a facility in Kinsale, where production of Lilly's latest diabetes and 澳洲幸运5官方开奖结果体彩网:obesity treatments began last year. 

Since 2020, Lilly said it has committed more than $20 ওbillion to investments in the U.S. and E💝urope.

Shares of Eli Lilly are up about 60% in 2024.